Electromagnetic fields join the fight against pancreatic cancer

NCT ID NCT06576115

Recruiting now Disease control Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer that has spread will receive the combined treatment. The main goal is to see how many patients are alive without their cancer getting worse after six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48021, United States
Karmanos Cancer Institute at McLaren Clarkston
RECRUITING

Clarkston, Michigan, 48346, United States
Karmanos Cancer Institute at McLaren Flint
RECRUITING

Flint, Michigan, 48532, United States
Karmanos Cancer Institute at McLaren Greater Lansing
RECRUITING

Lansing, Michigan, 48910, United States
Karmanos Cancer Institute at McLaren Lapeer Region
RECRUITING

Lapeer, Michigan, 48446, United States
Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey
RECRUITING

Petoskey, Michigan, 49770, United States
Karmanos Cancer Institute at McLaren Port Huron
RECRUITING

Port Huron, Michigan, 48060, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.